GTG - Genetic Technologies Limited
ASX
->
Healthcare
->
Diagnostics & Research
Fitzroy,
Australia
Type: Equity
GTG price evolution
GTG
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.02 | $1.02 | $3.73 | $3.73 |
| Short term investments | $0.02 | $0.02 | ||
| Net receivables | $2.13 | $2.13 | $1.12 | $1.12 |
| Inventory | $0.21 | $0.21 | $0.4 | $0.4 |
| Total current assets | $3.7 | $3.7 | $5.72 | $5.72 |
| Long term investments | ||||
| Property, plant & equipment | $0.26 | $0.26 | $0.43 | $0.43 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $6.19 | $6.19 | $8.47 | $8.47 |
| Current liabilities | ||||
| Accounts payable | $1.46 | $1.46 | $1.92 | $1.92 |
| Deferred revenue | ||||
| Short long term debt | $0.85 | $0.85 | $0.3 | $0.3 |
| Total current liabilities | $4.2 | $4.2 | $3.42 | $3.42 |
| Long term debt | $0.02 | $0.02 | $0.08 | $0.08 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.36 | $4.36 | $3.65 | $3.65 |
| Shareholders' equity | ||||
| Retained earnings | -$166.38 | -$166.38 | -$160.78 | -$160.78 |
| Other shareholder equity | $4.39 | $4.39 | $4.25 | $4.25 |
| Total shareholder equity | $1.83 | $1.83 | $4.81 | $4.81 |
| (in millions $) | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.02 | $7.85 | $11.73 | $20.9 |
| Short term investments | $0.02 | $0.02 | $0.01 | $0 |
| Net receivables | $2.13 | $1.92 | $2.42 | $1.07 |
| Inventory | $0.21 | $0.33 | $0.4 | $0.08 |
| Total current assets | $3.7 | $10.5 | $14.72 | $22.24 |
| Long term investments | ||||
| Property, plant & equipment | $0.26 | $0.6 | $0.95 | $0.64 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $6.19 | $14.86 | $20.8 | $22.97 |
| Current liabilities | ||||
| Accounts payable | $1.46 | $0.84 | $1.15 | $0.27 |
| Deferred revenue | ||||
| Short long term debt | $0.85 | $0.3 | $0.26 | $0.18 |
| Total current liabilities | $4.2 | $3.31 | $3.81 | $1.41 |
| Long term debt | $0.02 | $0.23 | $0.39 | $0.02 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $4.36 | $3.69 | $4.37 | $1.44 |
| Shareholders' equity | ||||
| Retained earnings | -$166.38 | -$156.72 | -$150.21 | -$132.04 |
| Other shareholder equity | $4.39 | $6.54 | $11.5 | $11.03 |
| Total shareholder equity | $1.83 | $11.16 | $16.43 | $21.53 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.4 | $2.4 | $2.48 | $2.48 |
| Cost of revenue | $1 | $1 | $0.88 | $0.88 |
| Gross Profit | $1.4 | $1.4 | $1.6 | $1.56 |
| Operating activities | ||||
| Research & development | $0.18 | $0.18 | $0.2 | $0.2 |
| Selling, general & administrative | $2.95 | $2.95 | $2.9 | $2.9 |
| Total operating expenses | $5.12 | $5.12 | $5.02 | $5.02 |
| Operating income | -$2.72 | -$2.72 | -$2.54 | -$2.54 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.02 | -$0.02 | -$0.01 | -$0.01 |
| Net income | ||||
| Net income | -$2.8 | -$2.8 | -$3.21 | -$3.21 |
| Income (for common shares) | -$2.8 | -$2.8 | -$3.21 | -$3.21 |
| (in millions $) | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.67 | $10.35 | $9.22 | $0.12 |
| Cost of revenue | $3.76 | $4.34 | $3.01 | $0.31 |
| Gross Profit | $5.91 | $6.01 | $6.2 | -$0.19 |
| Operating activities | ||||
| Research & development | $0.75 | $1.28 | $0.71 | $3.11 |
| Selling, general & administrative | $11.7 | $10.8 | $10.31 | $5.26 |
| Total operating expenses | $20.27 | $20.76 | $16.76 | $7.18 |
| Operating income | -$10.59 | -$10.42 | -$7.54 | -$7.06 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.16 | -$0.03 | ||
| Interest expense | -$0.05 | -$0.03 | -$0.01 | $0.02 |
| Net income | ||||
| Net income | -$12.02 | -$11.75 | -$7.13 | -$7.08 |
| Income (for common shares) | -$12.02 | -$11.75 | -$7.13 | -$7.08 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$2.8 | -$2.8 | -$3.21 | -$3.21 |
| Operating activities | ||||
| Depreciation | $0.13 | $0.13 | $0.14 | $0.14 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$2.83 | -$2.83 | -$2.01 | -$2.01 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0 | -$0.01 | -$0.01 |
| Investments | ||||
| Total cash flows from investing | $0.01 | $0.01 | $0.04 | $0.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.29 | $1.29 | ||
| Net borrowings | $0.21 | $0.21 | -$0.09 | -$0.09 |
| Total cash flows from financing | $1.5 | $1.5 | -$0.09 | -$0.09 |
| Effect of exchange rate | -$0.08 | -$0.08 | ||
| Change in cash and equivalents | -$1.35 | -$1.35 | -$2.06 | -$2.06 |
| (in millions $) | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2022 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$12.02 | -$11.75 | -$7.13 | -$7.08 |
| Operating activities | ||||
| Depreciation | $0.54 | $0.53 | $0.45 | $0.48 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$9.68 | -$9.72 | -$5.66 | -$6.3 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.02 | -$0.06 | -$0.75 |
| Investments | ||||
| Total cash flows from investing | $0.12 | -$0.31 | -$3.46 | -$0.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.58 | $7.17 | $15.9 | |
| Net borrowings | $0.25 | -$0.34 | -$0.27 | -$0.24 |
| Total cash flows from financing | $2.82 | $5.92 | -$0.28 | $13.69 |
| Effect of exchange rate | -$0.16 | $0.16 | $0.36 | $0.01 |
| Change in cash and equivalents | -$6.83 | -$3.88 | -$9.17 | $6.69 |
News
|
Avidity Biosciences becomes Novartis' $12B prize
Rolling Out
26 Oct 2025
|
|
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through...
Medical Xpress
24 Oct 2025
|
|
Talk To Your DNA: Startup Bystro AI Launches ChatGPT For Genetics To Decode...
Benzinga · via Yahoo Tech
24 Oct 2025
|
|
KFSHRC Integrates Gene Therapy Into Routine Clinical Care, Advancing Precision...
The National Law Review
23 Oct 2025
|
|
Creating luminescent biomaterials from wood
Phys.org
22 Oct 2025
|
|
Sperm From Older Men Have More Genetic Mutations
Wired News
21 Oct 2025
|
|
How Patient-Derived Models Are Empowering Neurodegenerative Disease Drug...
Technology Networks
20 Oct 2025
|
|
Vets from around globe gather in Orlando to talk care of creatures great and...
Florida Today · via Yahoo News
21 Feb 2025
|
|
Lost in the Chart: How Medicine Fails Adopted Adults
Medscape
21 Feb 2025
|
|
Autonomous sortie scheduling for carrier aircraft fleet under towing mode |...
Newswise
21 Feb 2025
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $9.76M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$12.02M |
| Revenue Q/Q | -10.78% |
| Revenue Y/Y | -5.79% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -163.98% |
| ROE | -362.05% |
| Debt/Equity | 2.38 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.88 |
| Quick ratio | 0.83 |